BIA regional focus: advanced therapies in the South West
Thursday 22 April 2021
The BIA is delighted to announce a South West regional event, this year taking place in virtual format, which will focus on advanced therapies in the South West of the UK.
There have been lots of exciting developments and success stories from the region in recent months, across the full developmental pathway, from developing very early stage start-ups through to expanding well-established companies.
We will see presentations on a number of these successes, followed by a panel discussion in which we will consider why the South West has been at the centre of all of these stories, and what can be done to maintain and build on these in future.
The afternoon will end with a chance to network remotely using Remo, a platform designed to mimic in-person networking as closely as possible.
15.00 Sign in and networking
15.15 BIA update
15:25 Presentations followed by panel discussion and Q&A, chaired by Angela Osborne (eXmoor)
Moin Saleem, Purespring / University of Bristol
Carolyn Porter, Cytoseek
Paul Lloyd-Evans, NHS Blood and Transplant
Each presentation will be 10 minutes, with the panel discussion and Q&A taking the remaining time
17:30 Event closes
We are excited to bring you this BIA regional focused networking event in virtual format.
You will be able to join us online to network and, similar to an in-person event, move from virtual table to table to mingle with other attendees. The platform we will be using also includes useful features which will allow you to message directly with other attendees and share LinkedIn details to connect. There is also a general chat for all attendees.
During the presentations/discussion you will be able to submit and vote on audience questions and we will try our best to cover everything in the time allocated.
What are the technical requirements to attend the virtual event?
- There is no software installation or download required.
- Please attend using a laptop or desktop computer with audio and video capabilities (webcam and microphone).
- You will need to use one of the supported browsers to have the best user experience:
Chrome, Safari, or Firefox.
- Please do a system check in advance of the event, to ensure you will be able to join without issue.
If your company has firewalls or browsing restrictions in place, please test your connection and liaise with your IT team in advance to ensure you are able to fully participate in the event.
BIA members: Free
Non-members: £30 +VAT
By registering for this event you accept our Terms & Conditions.
In case of any issues registering for the event, please contact us at firstname.lastname@example.org
Steve Bates has been the CEO of the UK Bioindustry Association since 2012. He currently chairs the International Council of Biotech Associations and has been a Board member of Europabio since 2015. Steve is the visible face of the vibrant UK life sciences industry to government and media. He sits on the UK’s Life Sciences Council and Life Sciences Industrial Strategy Implementation Board. Steve has championed with government effective industrial incentives like the Biomedical Cataylst which have crowded-in private sector investment into UK SMES. He has forged links for the sector across the USA, Europe and in China. In his time at the BIA Steve has developed new member groups focused on cell and gene therapy, genomics and engineered biology. A strong advocate of partnership working, Steve champions sector collaboration with research charities and academia. Proud to lead an organisation with a diverse Board with over 40% female representation, Steve is committed to next generation talent and developing the skills needed for the sector to flourish. Before the BIA, Steve worked for Genzyme and as an advisor to the UK Government of Tony Blair. He was made OBE for services to innovation in 2017.
As the Head of the CBC, Dr Paul Lloyd-Evans has overall management responsibility. He joined the CBC in 2000 as Deputy Manager and Senior Development Scientist. As a deputy, he gained several years’ experience in operating under a GMP quality system and the management of the facility before becoming the Head of the CBC in 2007. Prior to his, he worked as Clinical Scientist at the International Blood Group Reference Laboratory undertaking research into human antibody engineering. Paul previously gained a BSc and PhD at the University of Wales, Bangor before undertaking post-doctoral studies at the University of Wales, Swansea.
Angela has over 30 years’ experience in biopharmaceutical and cell and gene therapy businesses, processes and facilities. Angela works closely with clients to guide and support them through new product expansion projects, starting from the strategic business review, ensuring the early definition of technical requirements is focussed on the business benefits and that the final solution delivers these benefits.
Angela is most at home outdoors and can often be found roaming the coastal pathways of Exmoor, on epic adventures with her campervan, riding her purebred Arab or working with animals on her small holding.
Carolyn is CEO of CytoSeek a spin-out company from University of Bristol. CytoSeek is a discovery-stage biotech company developing the next generation of cell therapies to treat cancer using its pioneering cell-membrane augmentation technology. CytoSeek is applying its technology to enable development of more effective CAR-T cell therapies for the treatment of solid tumours. Carolyn has 20 years leadership experience working with spin-out companies in the Oxford ecosystem and previously held roles in Novartis and Chiron.
Moin Saleem is Founder and Chief Scientific Officer of Purespring Therapeutics, one of the first AAV gene therapy companies focused on the kidney globally. It has been founded around the seminal work of Moin as Head of Bristol Renal, where he heads a world leading group researching glomerular diseases. Purespring will seek to advance gene therapies for the treatment of chronic renal diseases that are currently poorly addressed with existing treatments.
Moin is also Professor of Paediatric Renal Medicine at the University of Bristol, where he set up his own independent laboratory programme in glomerular cell biology in Bristol, and has served as a consultant paediatric nephrologist since 1999. He now heads Bristol Renal, a glomerular research group of approximately 45 researchers, covering all areas from cell biology, transgenic models and population cohorts and genetics. His main focus is on podocyte biology. He was the originator of the UK Renal Rare Disease Registry (RaDaR), and he currently leads the UK nephrotic syndrome study (NephroS), as well as a major industry-academic collaboration termed NURTuRE (National Unified Renal Translational Research Enterprise). He is PI on several MRC projects, including Stratified Medicine, laboratory project grants and a Global Challenges programme.